• ACCENT trial achieves 31% response rate, superior to chemotherapy alone
• Two patients achieve complete responses, including one with pathological complete response
• Second trial of narmafotinib with FOLFIRINOX initiated in US and Australia

Amplia Therapeutics Limited (ASX: ATX) has announced further progress across its small molecule, focal adhesion kinase (FAK) inhibitor program and released its Appendix 4C Cash Flow Report for the quarter ending 30 June 2025. Key highlights include the ACCENT trial achieving a 31% response rate for narmafotinib combined with chemotherapy, superior to chemotherapy alone (23%). Two patients also achieved complete responses, including one with a rare pathological complete response in metastatic pancreatic cancer. Progress has been made in initiating a second trial of narmafotinib, combining it with FOLFIRINOX chemotherapy in the USA and Australia, with ethics approvals now secured for both regions. The company also appointed Dr. Jason Lickliter as Chief Medical Officer and presented ACCENT trial data at the American Association of Cancer Research annual meeting. Amplia finished the quarter with a cash position of $7.0 million and expects to receive a $3.8 million R&D tax incentive refund in the September 2025 quarter. The company also announced a $27.5 million capital raise to support ongoing clinical activities and additional planned activities, funding the company into 2027.

The company expects to continue collecting, analyzing and reporting data from the ongoing ACCENT trial and progress the FOLFIRINOX and narmafotinib combination trial in the USA and Australia over the coming months.

Amplia will focus on interactions with regulatory agencies, particularly the US FDA, in the coming months as it continues to advance its FAK inhibitor program.